The risk of nail changes with taxane chemotherapy: a systematic review of the literature and meta-analysis

Capriotti, Kara; Capriotti, Joseph; Lessin, Stuart R.; Wu, Shenhong; Goldfarb, Shari; Belum, Viswanath Reddy; Lacouture, Mario E.

doi:10.1111/bjd.13743

Cited by 55 publications

(53 citation statements)

References 7 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, the overall incidence of taxane-induced nail changes has been systematically investigated [134]; all-grade incidence was 43.7% with paclitaxel (95% CI: 18.0–73.3%) and 34.9% (95% CI: 29.9–40.2%) with docetaxel. For the latter, the relative risk was 77.74 (95% CI: 41.88–144.32; p <0.001) as compared to controls.…”

Section: Hair and Nail Changesmentioning

confidence: 99%

“…While mucositis appears to affect 15% of patients, it tends to be less severe (<2% are Grade 3) [157]. Nail changes are also frequent with nab-paclitaxel [159], with an estimated overall all-grade incidence of 19.4% (95% CI: 11.8–30.3%) [134]. Finally, to the best of our knowledge, HFS has, to date, not been reported with nab-paclitaxel.…”

Section: Nab-paclitaxelmentioning

confidence: 99%

See 1 more Smart Citation

Dermatological adverse events with taxane chemotherapy

Sibaud

LeBoeuf

Roché

et al. 2016

European Journal of Dermatology

177

179

View full text Add to dashboard Cite

Taxanes (docetaxel and paclitaxel) are among the most commonly prescribed anticancer drugs approved for the treatment of metastatic or locally advanced breast, non-small cell lung, prostate, gastric, head and neck, and ovarian cancers, as well as in the adjuvant setting for operable node-positive breast cancers. Although the true incidence of dermatological adverse events (AEs) in patients receiving taxanes is not known, and has never been prospectively analysed, they clearly represent one of the major AEs associated with these agents. With an increase in the occurrence of cutaneous AEs during treatment with novel targeted and immunological therapies when used in combination with taxanes, a thorough understanding of reactions attributable to this class is imperative. Moreover, identification and management of dermatological AEs is critical for maintaining the quality of life in cancer patients and for minimizing dose modifications of their antineoplastic regimen. This analysis represents a systematic review of the dermatological conditions reported with the use of these drugs, complemented by experience at comprehensive cancer centres. The conditions reported herein include skin, hair, and nail toxicities. Lastly, we describe the dermatological data available for the new, recently FDA-and EMA- approved, solvent-free nab-paclitaxel.

show abstract

Section: Hair and Nail Changesmentioning

confidence: 99%

Section: Nab-paclitaxelmentioning

confidence: 99%

Dermatological adverse events with taxane chemotherapy

Sibaud

LeBoeuf

Roché

et al. 2016

European Journal of Dermatology

177

179

View full text Add to dashboard Cite

show abstract

“…A systematic review and meta-analysis investigated the risk of nail abnormalities associated with taxanes chemotherapy, published in 2015, found a global incidence of nail abnormalities in 43.7% in patients using paclitaxel and 34.9% with docetaxel. The relative risk of developing nail abnormalities during treatment with this class of drugs was 77.4 (p <0.001 and 95% CI 41.88 -144.32) [6].…”

Section: Discussionmentioning

confidence: 94%

Nail Changes Due To Docetaxel Therapy: Case Report

Gm¹,

Dlv²,

Amorim³

et al. 2017

CRDOA

View full text Add to dashboard Cite

We report a case of 72 years old man, with prostate cancer, under chemotherapy treatment with docetaxel, referred to the dermatologist by the assistant oncology due to painful ungual lesions. The dermatological exam showed onycholysis, subungual hemorrhages and subungual abscess, affecting most of his fingernails. Since the ungual changes were secondary to docetaxel, the relevant literature was reviewed and it is presented in this case report.

show abstract

“…Nail changes occur with 34.9% and 17.2% of patients receiving taxanes and EGFR inhibitors, respectively 20,21. It has been reported that taxanes are associated most commonly with erythema, edema, exudate, suppuration, and onycholysis.…”

Section: Discussionmentioning

confidence: 99%

Chemotherapy-associated paronychia treated with 2% povidone–iodine: a series of cases

Capriotti¹,

Capriotti²,

Pelletier³

et al. 2017

CMAR

View full text Add to dashboard Cite

BackgroundNail changes are known to occur during the use of chemotherapy for a variety of malignancies, particularly those treated with taxanes and EGFR inhibitors. There are currently no actively recruiting prospective clinical trials investigating potential treatments. There are also no US Food and Drug Administration-approved medical treatments for chemotherapy-associated paronychia and no consensus on the best way to treat these common chemotherapy-induced events.MethodsA retrospective review of all cases presenting to a single dermatology private practice from June 2016 to January 2017 identified nine patients with chemotherapy-associated paronychia seeking treatment. Each patient was prescribed a topical solution comprised of 2% povidone–iodine in a dimethylsulfoxide vehicle that was prepared by a licensed compounding pharmacy. Patients were seen at 3 week and 6 week follow-up visits.ResultsAll 9/9 patients demonstrated complete or partial resolution. The number of nails involved for each patient ranged from 4–12. There were a total of 58 nails affected in the case series, and 44/58 (76%) resolved overall. The treatment was well tolerated.ConclusionThe topical povidone–iodine/dimethylsufoxide solution described is very effective in alleviating the signs and symptoms of paronychia associated with chemotherapy. This novel combination warrants further investigation in randomized, controlled trials to further elucidate its clinical utility.

show abstract

The risk of nail changes with taxane chemotherapy: a systematic review of the literature and meta-analysis

Cited by 55 publications

References 7 publications

Dermatological adverse events with taxane chemotherapy

Dermatological adverse events with taxane chemotherapy

Nail Changes Due To Docetaxel Therapy: Case Report

Chemotherapy-associated paronychia treated with 2% povidone–iodine: a series of cases

Contact Info

Product

Resources

About

The risk of nail changes with taxane chemotherapy: a systematic review of the literature and meta-analysis

Cited by 55 publications

References 7 publications

Dermatological adverse events with taxane chemotherapy

Dermatological adverse events with taxane chemotherapy

Nail Changes Due To Docetaxel Therapy: Case Report

Chemotherapy-associated paronychia treated with 2% povidone&ndash;iodine: a series of cases

Contact Info

Product

Resources

About

Chemotherapy-associated paronychia treated with 2% povidone–iodine: a series of cases